Orchestra BioMed is a U.S.-based developer of cardiovascular disease drugs that focuses on unmet cardiovascular disease needs. Its core innovation and product development expertise is in areas such as drug delivery, interventional devices, bioelectronics, and neuromodulation. Product candidates include Virtue Sirolimus-Eluting Balloon for Arterial Disease and BackBeat Cardiac Neuromodulation Therapy for Hypertension. Orchestra BioMed recently received $110 million in Series D financing, with investments from SternAegis Ventures, Terumo, Perceptive Advisors, RTW Investments, and Medtronic.
This article is reproduced from: https://www.itjuzi.com/investevent/13325843
This site is for inclusion only, and the copyright belongs to the original author.